TY - JOUR
T1 - Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors
T2 - A prospective cohort study
AU - D’costa, Matthew R.
AU - Haley, William E.
AU - Mara, Kristin C.
AU - Enders, Felicity T.
AU - Vrtiska, Terri J.
AU - Pais, Vernon M.
AU - Jacobsen, Steven J.
AU - McCollough, Cynthia H.
AU - Lieske, John C.
AU - Rule, Andrew David
N1 - Funding Information:
Dr. Lieske reports grants from Alnylam, grants from Dicerna, grants from Retrophin, grants from Oxthera, grants from Siemens, other from Orfan, outside the submitted work. Dr. Rule reports grants from National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, during the conduct of the study. Dr. McCollough reports grants from Siemens AG, outside the submitted work. All of the remaining authors have nothing to disclose.
Funding Information:
This project was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (Mayo Clinic O’Brien Urology Research Center, DK100227 and DK83007) and made possible by the Rochester Epidemiology Project (AG034676) and the National Center for Advancing Translational Sciences (UL1 TR002377) from the National Institutes of Health, US Public Health Service.
Publisher Copyright:
© 2019 by the American Society of Nephrology.
PY - 2019/7
Y1 - 2019/7
N2 - Background Meaningful interpretation of changes in radiographic kidney stone burden requires understanding how radiographic recurrence relates to symptomatic recurrence and how established risk factors predict these different manifestations of recurrence. Methods We recruited first-time symptomatic stone formers from the general community in Minnesota and Florida. Baseline and 5-year follow-up study visits included computed tomography scans, surveys, and medical record review. We noted symptomatic recurrence detected by clinical care (through chart review) or self-report, and radiographic recurrence of any new stone, stone growth, or stone passage (comparing baseline and follow-up scans). To assess the prediction of different manifestations of recurrence, we used the Recurrence of Kidney Stone (ROKS) score, which sums multiple baseline risk factors. Results Among 175 stone formers, 19% had symptomatic recurrence detected by clinical care and 25% detected by self-report; radiographic recurrence manifested as a new stone in 35%, stone growth in 24%, and stone passage in 27%. Among those with a baseline asymptomatic stone (54%), at 5 years, 51% had radiographic evidence of stone passage (accompanied by symptoms in only 52%). Imaging evidence of a new stone or stone passage more strongly associated with symptomatic recurrence detected by clinical care than by self-report. The ROKS score weakly predicted one manifestation—symptomatic recurrence resulting in clinical care (c-statistic, 0.63; 95% confidence interval, 0.52 to 0.73)—but strongly predicted any manifestation of symptomatic or radiographic recurrence (5-year rate, 67%; c-statistic, 0.79; 95% confidence interval, 0.72 to 0.86). Conclusions Recurrence after the first stone episode is both more common and more predictable when all manifestations of recurrence (symptomatic and radiographic) are considered.
AB - Background Meaningful interpretation of changes in radiographic kidney stone burden requires understanding how radiographic recurrence relates to symptomatic recurrence and how established risk factors predict these different manifestations of recurrence. Methods We recruited first-time symptomatic stone formers from the general community in Minnesota and Florida. Baseline and 5-year follow-up study visits included computed tomography scans, surveys, and medical record review. We noted symptomatic recurrence detected by clinical care (through chart review) or self-report, and radiographic recurrence of any new stone, stone growth, or stone passage (comparing baseline and follow-up scans). To assess the prediction of different manifestations of recurrence, we used the Recurrence of Kidney Stone (ROKS) score, which sums multiple baseline risk factors. Results Among 175 stone formers, 19% had symptomatic recurrence detected by clinical care and 25% detected by self-report; radiographic recurrence manifested as a new stone in 35%, stone growth in 24%, and stone passage in 27%. Among those with a baseline asymptomatic stone (54%), at 5 years, 51% had radiographic evidence of stone passage (accompanied by symptoms in only 52%). Imaging evidence of a new stone or stone passage more strongly associated with symptomatic recurrence detected by clinical care than by self-report. The ROKS score weakly predicted one manifestation—symptomatic recurrence resulting in clinical care (c-statistic, 0.63; 95% confidence interval, 0.52 to 0.73)—but strongly predicted any manifestation of symptomatic or radiographic recurrence (5-year rate, 67%; c-statistic, 0.79; 95% confidence interval, 0.72 to 0.86). Conclusions Recurrence after the first stone episode is both more common and more predictable when all manifestations of recurrence (symptomatic and radiographic) are considered.
UR - http://www.scopus.com/inward/record.url?scp=85069236096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069236096&partnerID=8YFLogxK
U2 - 10.1681/ASN.2018121241
DO - 10.1681/ASN.2018121241
M3 - Article
C2 - 31175141
AN - SCOPUS:85069236096
SN - 1046-6673
VL - 30
SP - 1251
EP - 1260
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 7
ER -